Peter Klivenyi, MD PhD
Affiliations: | Neurology | University of Pécs, Hungary, Pécs, Hungary |
Google:
"Peter Klivenyi"Mean distance: 17.48 (cluster 28)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Zádori D, Szalárdy L, Reisz Z, et al. (2020) Clinicopathological Relationships in an Aged Case of DOORS Syndrome With a p.Arg506X Mutation in the Gene. Frontiers in Neurology. 11: 767 |
| Salamon A, Zádori D, Szpisjak L, et al. (2020) Fixed-dose combination therapy for Parkinson's disease with a spotlight on entacapone in the past 20 years: a reduced pill burden and a simplified dosing regime. Expert Opinion On Pharmacotherapy. 1-14 |
| Takáts A, Aschermann Z, Vécsei L, et al. (2020) [Advanced Parkinson's disease characteristics in clinical practice: Results from the OBSERVE-PD study and sub-analysis of the Hungarian data]. Ideggyogyaszati Szemle. 73: 261-268 |
| Nánási N, Veres G, Cseh EK, et al. (2020) The assessment of possible gender-related effect of endogenous striatal alpha-tocopherol level on MPTP neurotoxicity in mice. Heliyon. 6: e04425 |
| Salamon A, Maszlag-Török R, Veres G, et al. (2020) Cerebellar Predominant Increase in mRNA Expression Levels of Sirt1 and Sirt3 Isoforms in a Transgenic Mouse Model of Huntington's Disease. Neurochemical Research |
| Boros FA, Maszlag-Török R, Vécsei L, et al. (2020) Increased level of NEAT1 long non-coding RNA is detectable in peripheral blood cells of patients with Parkinson's disease. Brain Research. 1730: 146672 |
| Salamon A, Zádori D, Szpisjak L, et al. (2019) Neuroprotection in Parkinson's disease: facts and hopes. Journal of Neural Transmission (Vienna, Austria : 1996) |
| Illés A, Csabán D, Grosz Z, et al. (2019) The Role of Genetic Testing in the Clinical Practice and Research of Early-Onset Parkinsonian Disorders in a Hungarian Cohort: Increasing Challenge in Genetic Counselling, Improving Chances in Stratification for Clinical Trials. Frontiers in Genetics. 10: 1061 |
| Salamon A, Zádori D, Szpisjak L, et al. (2019) Opicapone for the treatment of Parkinson's disease: an update. Expert Opinion On Pharmacotherapy. 1-7 |
| Boros FA, Török R, Vágvölgyi-Sümegi E, et al. (2019) Assessment of risk factor variants of LRRK2, MAPT, SNCA and TCEANC2 genes in Hungarian sporadic Parkinson's disease patients. Neuroscience Letters. 706: 140-145 |